Table of Contents
Penny stocks are a polarizing corner of the market. Some traders swear by their explosive potential, while others warn they’re a fast track to losing your shirt. The truth lies somewhere in between. These low-priced stocks—typically trading under $5—can deliver life-changing gains, but they come with extreme volatility and real risks.
I’ve screened hundreds of penny stocks to find seven that stand out for their catalysts, financial health, or unique market positions. These aren’t tips—they’re starting points for your own research. Let’s dig into each one.
1. Tonix Pharmaceuticals (TNXP)
A Biotech Bet on Fibromyalgia
Tonix is developing TNX-102 SL, a sublingual formulation of cyclobenzaprine for fibromyalgia. Phase 3 results showed statistically significant pain reduction. If approved, it could capture a chunk of the $3 billion US fibromyalgia market. The company also has a pipeline for PTSD and COVID-19 long-haul symptoms.
Risks: Biotech binary events. A failed trial or FDA rejection could crater the stock. Cash burn is also a concern—they raised capital via stock offerings in 2024, diluting shareholders.
2. Sundial Growers (SNDL)
Cannabis Consolidation Play
Sundial has transformed from a struggling Canadian producer into a cash-rich consolidator. They own a 63% stake in Nova Cannabis and hold over $200 million in cash. The company is acquiring distressed assets at bargain prices, aiming for profitability as US legalization looms.
Risks: Cannabis stocks remain volatile. US federal legalization is uncertain, and Sundial’s acquisitions haven’t yet yielded consistent positive earnings.
3. D-Wave Quantum (QBTS)
Quantum Computing at a Penny
D-Wave is the only company selling both quantum annealing and gate-model systems. They have a working 5,000-qubit Advantage system and commercial customers like Mastercard and Lockheed Martin. Revenue grew 50% YoY in 2024.
Risks: Quantum computing is still early-stage. D-Wave posted a net loss of $70 million in 2024. Competition from IBM and Google is intense.
4. Palisade Bio (PALI)
Ulcerative Colitis Candidate
Palisade is developing LB1148, a drug to treat post-surgical adhesions and ulcerative colitis. Phase 1b data showed reduced inflammation markers. The total addressable market for UC treatments exceeds $10 billion.
Risks: The stock has a low market cap (~$10 million) and minimal institutional ownership. A failed trial could wipe out shareholders.
5. GeoVax Labs (GOVX)
Vaccines Beyond COVID
GeoVax has a novel MVA-VLP vaccine platform. Their lead candidate, GX-19, targets COVID-19 and has shown strong T-cell responses. They’re also developing vaccines for Lassa fever, Zika, and malaria, with government grants funding much of the work.
Risks: The COVID vaccine market is crowded. GeoVax has no approved products and relies on external funding.
6. Rekor Systems (REKR)
AI Traffic Management
Rekor provides AI-powered license plate recognition and traffic analytics to law enforcement and toll agencies. Revenue grew 40% in 2024, and they’ve secured contracts with several US states. The smart city market is expected to hit $1 trillion by 2028.
Risks: The company is not yet profitable. Competition from Motorola Solutions and Flock Safety is fierce.
7. Zomedica (ZOM)
Veterinary Diagnostics
Zomedica sells the TRUFORMA diagnostic platform for cats and dogs, detecting thyroid and adrenal diseases. They have over 2,000 placements in vet clinics. Revenue grew 25% in 2024, and the pet diagnostics market is expanding rapidly.
Risks: TRUFORMA revenue is still small (~$15 million annually). The company relies on a single product line.
How to Approach Penny Stocks
Penny stocks require a different playbook. Here are a few rules I follow:
- Position size: Never allocate more than 5% of your portfolio to penny stocks. They can drop 50% in a day.
- Liquidity: Check average volume. Illiquid stocks are easy to buy but hard to sell without moving the price.
- Catalysts: Only invest if there’s a clear event—FDA decision, earnings, contract win—that could drive the stock.
- Insider ownership: High insider ownership signals confidence. Look for 10%+.
For a broader investment strategy, consider reading our J.P. Morgan Investing Review to see how self-directed platforms compare for penny stock trading.
Tax Implications for Penny Stock Profits
If you hit a home run, remember that short-term capital gains (stocks held under a year) are taxed as ordinary income—up to 37%. Long-term gains get preferential rates. Our guide on The Step-Up In Cost Basis And The Estate Tax Threshold explains how to minimize taxes on inherited stocks, but for active traders, tax-loss harvesting can offset gains.
Why Most Penny Stocks Fail
According to a study by the SEC, 70% of penny stock investors lose money. The reasons are predictable: pump-and-dump schemes, weak business models, and dilution. Many penny companies have no revenue or product. They survive by issuing new shares, which destroys shareholder value.
Before buying any penny stock, check the company’s SEC filings. Look at the balance sheet. If they have more debt than cash and no revenue, walk away.
Final Trade
Penny stocks can be a thrilling addition to a diversified portfolio, but they demand homework. The seven I’ve listed have real products, revenue, or catalysts—but they’re still speculative. Start small, set stop-losses, and never invest money you can’t afford to lose.
If real estate investing feels safer, our article on Paying For A Home Inspection Is Worth The Cost highlights why due diligence matters there too.
